Preexposure prophylaxis for HIV prevention

被引：32
作者：
Kelesidis T. [1 ]
Landovitz R.J. [2 ]
机构：
[1] Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA
[2] UCLA Center for Clinical AIDS Research and Education, David Geffen School of Medicine at UCLA, Los Angeles, CA 90035
来源：
Current HIV/AIDS Reports | 2011年 / 8卷 / 2期
关键词：
Antiretrovirals; HIV; Preexposure prophylaxis;
D O I：
10.1007/s11904-011-0078-4
中图分类号：
学科分类号：
摘要：
Reducing the incidence of HIV remains one of our greatest public health challenges. However, there is growing optimism that preexposure prophylaxis (PrEP) could have a major impact on preventing incident HIV infection. Recently presented data on the use of oral PrEP in men who have sex with men (MSM) have provided proof-of-principle for this strategy. Additional clinical trials are evaluating whether PrEP provides similar protection to risk groups other than MSM, such as heterosexual persons and injection drug users. Still unanswered questions include optimal dosing strategies, long-term safety, maximizing adherence and minimizing costs, addressing drug resistance in the face of PrEP failure, optimizing access, and assessing effects on risk behavior. Future implementation will be guided by the results of clinical trials in progress. This article provides a review of the data on the potential strengths and limitations of PrEP as an HIV prevention strategy, identifies challenges to implementation of this approach, and outlines knowledge gaps. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：94 / 103
页数：9
相关论文
共 56 条
  • [1] Landovitz R.J., Currier J.S., Clinical practice. Postexposure prophylaxis for HIV infection, N Engl J Med, 361, 18, pp. 1768-1775, (2009)
  • [2] Bailey R.C., Moses S., Parker C.B., Agot K., Maclean I., Krieger J.N., Williams C.F., Campbell R.T., Ndinya-Achola J.O., Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial, Lancet, 369, 9562, pp. 643-656, (2007)
  • [3] Abdool K.Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Et al., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science, 329, 5996, pp. 1168-1174, (2010)
  • [4] Vermund S.H., Van D.L., HIV prevention in women: Next steps, Science, 331, 6015, (2011)
  • [5] Kim J.H., Rerks-Ngarm S., Excler J.L., Michael N.L., HIV vaccines: Lessons learned and the way forward, Curr Opin HIV AIDS, 5, 5, pp. 428-434, (2010)
  • [6] Padian N.S., Buve A., Balkus J., Serwadda D., Cates Jr. W., Biomedical interventions to prevent HIV infection: Evidence, challenges, and way forward, Lancet, 372, 9638, pp. 585-599, (2008)
  • [7] Cohen M.S., Gay C., Kashuba A.D.M., Blower S., Paxton L., Narrative review: Antiretroviral therapy to prevent the sexual transmission of HIV-1, Annals of Internal Medicine, 146, 8, pp. 591-601, (2007)
  • [8] Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., Et al., Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men, N Engl J Med, 363, 27, pp. 2587-2599, (2010)
  • [9] Paxton L.A., Hope T., Jaffe H.W., Pre-exposure prophylaxis for HIV infection: What if it works?, Lancet, 370, 9581, pp. 89-93, (2007)
  • [10] Borroto-Esoda K., Vela J.E., Myrick F., Ray A.S., Miller M.D., In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine, Antiviral Therapy, 11, 3, pp. 377-384, (2006)
123456